Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

AstraZeneca signs MoU with Indian Diabetes Research Society (RSSDI) to empower 1 Crore Indian Diabetic patients by 2023

Posted On: 2020-11-27 10:21:15 (Time Zone: Arizona, USA)


AstraZeneca India (AstraZeneca Pharma India Limited), a leading science-led biopharmaceutical company, today signed a memorandum of understanding with the Research Society for Study of Diabetes in India (RSSDI). This MOU is aimed at digitising and driving correct awareness of Diabetes amongst people to prevent complications arising from the uncontrolled incidence of the disease.

RSSDI is the largest organisation of Diabetes health care professionals and researchers in Asia with around 6000 members from amongst physicians, diabetologists, endocrinologists, as well as paramedical personnel. The organisation has been instrumental in extensive research on Diabetes, as well as continuing diabetes education initiatives in India. As a key facet of this dual association, AstraZeneca unveiled a campaign-'Beyond Sugar', a three-year patient awareness program developed to benefit over 1 Crore people living with Diabetes across the country. This initiative will empower patients/caregivers to have conversations around Diabetes and make informed decisions about the management of the disease.

The International Diabetes Foundation Atlas on Diabetes shows that 1 in 11 people in south Asia have Diabetes and that India will have around 11.5 Crore diabetes patients by 2030. While 10% to 15% of the general population have Diabetes, a recent study suggested that 44% of patients hospitalised for Heart Failure (HF) have type 2 diabetes showcasing the steep correlation between Diabetes and HF. HF is a major health problem in India with post-admission mortality of 20%-30%. Chronic kidney diseases is associated with significant patient death and an increased risk of heart failure. Therefore, it is critical that Diabetes be controlled to decrease the incidence of HF and CKD in India.

Dr. Anil Kukreja, Vice President - Medical Affairs & Regulatory, AstraZeneca India, said "AstraZeneca has always been at the forefront of enabling patient-centric solutions for the management of non-communicable diseases. Despite currently available therapies, the awareness levels among the public is relatively low, resulting in uncontrolled Diabetes and additional complications of the heart and kidneys. The partnership between AstraZeneca and RSSDI will go a long way in supporting patient-centric digital awareness campaign and programs to raise awareness about Diabetes and its complications so that they can act early to manage or even prevent the complications".

Dr. Banshi Saboo, President - RSSDI and Organising Chairman 2020, said, "This partnership between RSSDI and AstraZeneca will result in increased awareness levels about Diabetes and its complications. Our vision is to touch 1 Crore lives in India over the next three years through this Digital patient-centric approach. In the COVID era, this digitally-powered initiative will also empower patients/caregivers to have better conversations with their doctors about the disease and make informed decisions in the management of Diabetes. All this will culminate towards shifting from the glucose centric management approach towards a holistic and an early Cardio-Renal focused management of type 2 diabetes."

Dr. Sanjay Agarwal, Secretary- RSSDI 2020, said, "Being the largest organisation of Diabetes doctors and researchers in Asia, RSSDI is always focused at elevating the patient outcomes in Diabetes with constant research and innovative solutions. Beyond Sugar is one such patient-centric initiative which will play a vital role along with our RSSDI state chapters to raise the awareness by leveraging social media and digital platforms. With the support of AstraZeneca, we aim to reach out to the patients, community and HCP to increase awareness about Diabetes and help patients initiate conversations about the prevention of complications in Diabetes."

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.4538.5 as compared to the previous close of Rs. 4506.75. The total number of shares traded during the day was 9656 in over 2165 trades.

The stock hit an intraday high of Rs. 4579.75 and intraday low of 4396.6. The net turnover during the day was Rs. 43330373.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

HDFC to sell 24.48% stake in Good Host for Rs. 232.81 crore

The Sandur Manganese & Iron Ores Limited commences Commercial Production of Phase I of 1 MTPA Iron and Steel Project

Aditya Birla Fashion and Retail Limited gets CCI nod for preferential issue to Flipkart

Sagar Cements Ltd board declares second interim dividend of Rs. 2

Strong Retail Demand: Indigo Paints IPO fully subscribed on Day 1

IndiGo transports over 2.1 Mn vaccine doses in 8 days across 16 locations

Agro Tech Foods Ltd Q3 FY2020-21 consolidated net profit at Rs. 8.14 crore

L&T Technology Services Ltd Q3FY21 consolidated net profit up QoQ to Rs. 186.1 crore

Confidence Petroleum India Ltd reports consolidated net profit of Rs. 20.35 crore in Q3FY21

Allsec Technologies Ltd posts Q3FY21 consolidated PAT of Rs. 8.87 crore

Sagar Cements Ltd Q3FY21 consolidated net profit at Rs. 49.67 crore

Bajaj Finserv Ltd posts Rs. 1289.96 crore consolidated PAT in Q3FY21

Oriental Aromatics Ltd Q3FY21 consolidated PAT up at Rs. 36.35 crore

Havells India Ltd board declares interim dividend of Rs. 3

Everest Industries Ltd Q3FY21 consolidated PAT slides QoQ to Rs. 5.38 crore

Tejas Networks Ltd Q3FY21 consolidated net profit at Rs. 9.23 crore

Havells India Ltd reports Rs. 350.14 crores consolidated PAT in Q3FY21

Indo Rama Synthetics India Ltd Q3FY21 consolidated net profit at Rs. 76.17 crore

Phillips Carbon Black Limited board declares interim dividend of Rs. 7

GMM Pfaudler Ltd Board approves 3rd interim dividend of Rs. 1

Laurus Labs Ltd completes acquisition of 72.55% in Richcore Lifesciences Pvt Ltd

Gulshan Polyols Ltd announces financial results for Q3FY21

HDFC Asset Management Company Ltd posts PAT of Rs. 369.26 crore in Q3FY21

VST Industries Ltd Q3FY21 PAT slips to Rs. 73.71 crore

Phillips Carbon Black Ltd posts Rs. 125.44 crores consolidated PAT in Q3 FY2020-21

GMM Pfaudler Ltd Q3FY21 consolidated PAT at Rs. 23.16 crore

Tanla partners with Microsoft to launch blockchain-enabled CPaaS platform, Wisely

Infosys Ltd launches Infosys Cortex

Sheetal Cool Products Limited receives approval certificate from Export Inspection Council

Quint Digital Media Ltd board approves 1:1 bonus issue

Bajaj Finance Ltd Q3FY21 consolidated net profit at Rs. 1145.98 crore

ACE develops Li-Ion Electric forklifts

CMI gets vendor approval from a prestigious Company

Sasken Technologies Ltd posts Rs. 33.90 crore consolidated PAT in Q3FY21

The Tinplate Company of India Ltd posts QoQ surge in PAT to Rs. 32.82 crore in Q3FY21

Udaipur Cement Works Ltd Q3FY21 net profit climbs to Rs. 15.55 crore

Quint Digital Media Ltd Q3FY21 PAT at Rs. 0.90 crore

LT Foods subsidiary acquires 30% stake in Leev, Netherlands

Radio City & Mid-day Award Top OTT Talent with the Second Edition of the Hitlist OTT Awards

Sterlite Technologies Ltd posts consolidated PAT of Rs. 86.64 crore in Q3FY21

The Federal Bank Ltd Q3FY21 consolidated PAT at Rs. 418.14 crore

Hindustan Zinc Ltd Q3FY21 net profit rises to Rs. 2200 crore

Cigniti signs up as a Medecision Liberation Strategic Partner

Karda Constructions reports strong turnaround in Q3 as construction activities resume post-lockdown

Newgen Software Technologies Ltd Q3FY21 consolidated PAT higher at Rs. 35.41 crore

Maruti Suzuki commences production and export of Jimny from India

Mindtree helps Aflac Simplify Claims Experience for Customers

Birla Precision Technologies Limited allots 84,31,703 Equity Shares at Rs. 5.93 to promoter

L&T Construction bags large contracts for its Power Transmission & Distribution Business in Bangladesh

AGEL commissions 150 MW Solar Power Plant at Kutchh, Gujarat, 3 months ahead of schedule



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020